Gyre Therapeutics GYRE
NASDAQ GYRE
$4.26 +0.03 (+0.71%)
At close: Nov 11, 2026 · 4:00 PM EST

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2009 - 2015)

Updated

Gyre Therapeutics (GYRE) recorded Asset Writedowns and Impairment of $134,000 in Q2 2015.

Analysis

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2009 - 2015) Analysis & Trends

For FY2014, Gyre Therapeutics reported Asset Writedowns and Impairment of $53,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Gyre Therapeutics 487.81 Mn 295.13 Mn 30.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 134,000.00
Sep 30, 2009 25,000.00
API Access

Gyre Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=GYRE&period=max&api_key=YOUR_API_KEY